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TARGETED THERAPIES FOR THYMIC MALIGNANCIES
Nicolas Girard  
Respiratory Medicine, Hospices Civils De Lyon, Bron/FRANCE
Thymic malignancies are rare epithelial tumors that may be aggressive and difficult to 
treat. Thymomas are usually localized to the anterior mediastinum and are frequently 
eligible for upfront surgical resection. However, nearly 30% of patients present with 
locally advanced tumor at time of diagnosis, and chemotherapy is then used to reduce 
the tumor burden, possibly allowing subsequent surgery and/or radiotherapy. Thymic 
carcinomas have a tendency towards metastatic spread, and systemic treatment is 
a major component in the multimodal strategy. Metastatic and recurrent thymic 
malignancies may similarly be treated with chemotherapy, with limited long-term 
efficacy, especially beyond first-line treatment. The molecular characterization of 
thymoma and thymic carcinoma recently led to identify potentially druggable targets; 
significant preclinical and clinical data are available for the EGF receptor (EGFR), the 
KIT/mast/stem-cell growth factor receptor, and the IGF-1 receptor (IGF-1R) pathways. 
While there is currently no rationale to recommend the use of EGFR tyrosine kinase 
inhibitors in thymoma or thymic carcinoma, the frequent overexpression of EGFR 
by epithelial tumor cells is a strong rationale for further evaluation of anti-EGFR 
monoclonal antibodies, such as cetuximab. A phase II trial is ongoing in unresectable 
locally advanced thymomas. KIT-mutant thymic carcinomas represent a small molecular 
subset of thymic tumors. The clinical relevance of KIT mutations is more limited than 
in other cancers such as gastro-intestinal stromal tumors, as KIT mutations are far less 
frequently observed, KIT expression does not correlate with the presence of mutations, 
and nonpretreated KIT mutants are not uniformly sensitive to imatinib. The use of 
second-generation multikinase inhibitors is then mandatory to inhibit the KIT signaling 
pathway. IGF-1R is overexpressed in 30% of thymomas and 80% of thymic carcinomas; 
results from a phase II with cixutumumab have recently been reported, showing 
promising response and survival rates. Another target of interest in thymic malignancies 
is neoangiogenesis, as activation of the Vascular Endothelial Growth Factor/VEGF-
Receptor signaling pathway has been correlated with tumor invasion, aggressive 
histology, and higher clinical stage. Only sparse data are available regarding the use of 
specific anti-angiogenic drugs. Besides bevacizumab and vascular disrupting agents, 
the reported effect of multikinase inhibitors, such as sunitinib or sorafenib, especially 
in KIT-wild-type thymic carcinomas, may be partially related to their antiangiogenic 
effect. Other molecular targets include histone deacetylase, with promising results 
reported with belinostat, and cyclin-dependant kinases, with specific inhibitors 
currently under investigation. Besides these predictive biomarkers, the identification 
of prognostic markers would help to better select patients with thymic malignancies 
for aggressive treatment, including postoperative radiotherapy and chemotherapy. 
However, the favorable outcome of thymoma after surgery and the highly significant 
prognostic value of complete resection make the identification of prognostic factors 
challenging. Integrated genomic analyses, including standard genomic, expression, 
and mutational profiling, but also next-generation sequencing, represent a new avenue 
for the identification of predictive and prognostic biomarkers. One example is the 
establishment of RNA-based and/or micro-RNA-based prognostic signatures, which 
will be evaluated in prospective studies, to assess their value as surrogate markers to 
predict the aggressiveness of a tumor. Taken together, these data show that the concept 
of personalized molecular medicine, which consists of establishing a therapeutic 
strategy based on the individual assessment of predictive and prognostic biomarkers, is 
applicable to rare tumors such as thymomas and thymic carcinomas. This paradigm shift 
will represent a major area of investigation in the next future.
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INDUCTION THERAPY THEN SURGERY
Marco Lucchi, Alfredo Mussi  
Cardiac And Thoracic Department, University Of Pisa, Pisa/ITALY
Stage of tumor and completeness of surgical resection have been shown major 
prognostic factors in thymoma patients. However a complete resection of thymomas, 
in case of locally advanced disease, can require extensive surgical resections or not 
be possible. Chemotherapy, especially with platinum regimens, has demonstrated 
radiographic response rates greater than 50%. Radiation therapy, already used to 
treat thymoma in patients who could not undergo complete surgical resection and 
as adjuvant postoperative therapy for patients with locally advanced disease, in a 
neoadjuvant setting has the potentiality to improve response rates and increase the rate 
of cure of unresectable disease. On the other hand, major concerns after neoadjuvant 
radiotherapy are the higher post-operative morbidity and how to treat the patients 
in case of incomplete resections (R1 or R2). Multimodality strategies, in case of 
invasive thymomas, are essentially trimodality treatments (surgery - radiotherapy - 
chemotherapy) with satisfying results; however, which integration is the best has still not 
been established. With the aim of evaluating the results of multidisciplinary approaches, 
we reviewed our experience in multimodality treatment of advanced stage (III-IVa) 
thymic tumors, focusing on the role of neoadjuvant chemotherapy. From 1976 to 2010, 
102 patients with Masaoka stage III and IVA thymic tumors underwent a multimodality 
treatment. Sixty-three patients underwent neoadjuvant chemotherapy, surgery and 
post-operative radiotherapy; 39 patients were treated by primary surgery and post-
operative radiotherapy (n=26), chemotherapy (n=2) or chemo-radiotherapy (n=11). 
The neoadjuvant or adjuvant chemotherapy consisted of three courses of cisplatin, 
epidoxorubicin and etoposide, every 3 weeks. Adjuvant radiotherapy consisted of 45 Gy 
for complete resections or 60 Gy for incomplete resections. The pre-operative diagnosis 
of invasive thymomas was performed in a total of 44 cases: 25 by mediastinotomy, 11 
by VATS and 8 by needle biopsy. In 58 cases no pre-operative diagnosis was available, 
but in most of them a thymus related syndrome was present. Sixty-eight patients are 
still alive (61 disease-free) and 34 have died (4 disease-free). Overall 10-year survival 
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was 54.1% and 41.9% for stage III and IVA thymomas, respectively. The presence of 
a myasthenia gravis (p=0.04) and the neoadjuvant chemotherapy (p=0.002) affected 
survival significantly. The multimodality treatment of stage III e IVA thymic tumors 
allows in any case a good long-term outcome and, despite a not avoidable selection bias, 
the neoadjuvant chemotherapy improved the resecability rate and the survival of both 
stages of the disease. In many other advanced malignancies, significant improvements 
in response rate and overall survival have been observed after the addition of biologic 
therapies also in the neoadiuvant treatment. Actually there is an ongoing phase II 
clinical trial of cetuximab with cisplatin, doxorubicin, and cyclophosphamide in patients 
with locally advanced thymoma (NCT01025089). There is reason to think that a better 
genetic and biological knowledge of the thymoma will produce effective target therapies 
able to improve the results of current neoadjuvant regimens.
Keywords: thymoma, neoadjuvant chemotherapy, Surgery, survival
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SURGERY THEN ADJUVANT CHEMOTHERAPY, RT
Motoki Yano  
Oncology, Immunology And Surgery, Nagoya City University Graduate School Of 
Medical Sciences, Nagoya/JAPAN
Surgical resection has been advocated as the principal treatment of thymoma and the 
completeness of resection has been considered to be the most important determinant 
of long-term survival. In stage III thymomas, en-bloc resection of involved organs is 
required to achieve complete resection. However, we sometimes experience incomplete 
resection because of technical difficulties or the patients’ conditions. In such cases we 
have often selected postoperative radiotherapy. The efficacy of adjuvant chemotherapy 
and radiotherapy has been controversial. In our experience of stage III thymoma cases, 
we have not able to demonstrate the efficacy of adjuvant radiotherapy on overall or 
disease free survival. However, the efficacy of the postoperative irradiation on the local 
control of the residual lesions was apparent. In stage III thymoma patients pleural 
disseminated nodules were the most often observed form of recurrence (about 30 % 
of Stage III thymoma patients). Sooner or later, pleural disseminated recurrence will 
become the critical determinant of survival. A small number of pleural lesions may 
be cured by surgical resection or radiotherapy. However, a large number of pleural 
recurrent lesions are difficult to cure. Extrapleural pneumonectomy may be a possibly 
curable modality but not all thymoma patients with pleural lesions are the candidates 
for this operation. To prevent pleural disseminated recurrence, adjuvant chemotherapy 
for stage III thymoma patients even with complete resection may be considered. 
Unfortunately we do not have experience in adjuvant chemotherapy for stage III 
thymoma. Regarding to adjuvant chemotherapy, only small-sized or case reports are 
available. Randomized trial of chemotherapy for thymoma has not been attempted so far. 
A randomized controlled clinical trial of adjuvant chemotherapy for stage III thymoma 
patients conducted by ITMIG is eagerly awaited.
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PRIMARY CHEMOTHERAPY FOR THYMIC MALIGNANCIES
Heather Wakelee  
Medicine/Oncology, Stanford University School Of Medicine, Stanford/CA/UNITED 
STATES OF AMERICA
Thymic malignancies are rare making determination of optimal therapeutic strategies 
challenging. The disease is not often found in early stage as no screening exists and 
local symptoms such as cough, dyspnea or chest pain are uncommon, as are the 
paraneoplastic syndromes such as red cell aplasia, and myasthenia gravis which could 
lead to an earlier diagnosis. Surgical therapy is the standard for local disease, and 
for patients with Masaoka-Koga stage I thymomas the local control rates approach 
100% with surgery alone and control rates are above 90% for stage II disease with 
surgical resection alone. Unfortunately, close to 50% of patients with stage II disease 
will ultimately recur and the risk for recurrence is much higher for stage III and in 
thymic carcinoma. In stage III disease, the optimal approach either before or after 
surgical resection is unclear and there is even more uncertainty for thymic carcinoma 
management. Thymic malignancies are often identified at a time when they are not 
easily resectable and pre-operative therapy is an important component of care for many 
patients. Patients who are not able to achieve a complete resection at the time of surgery 
do poorly, and thus strategies to shrink the tumor and maximize the potential for a 
complete resection are critical. Complete tumor resection (R0) is the most important 
predictor of outcome in stage III thymomas with 5 year survivals of 93%, 65% and 
36% respectively for patients with the disease who had undergone complete versus 
subtotal versus no resection in a series of over 1000 patients.1 Though large trials are 
lacking, there is good data on combination chemotherapy regimens in the first line for 
advanced disease. Many of these regimens consist of a platinum drug (cisplatin), often 
in combination with an anthracycline, with other agents such as cyclophosphamide, 
vincristine, ifosphamide and etoposide also investigated. Unfortunately, given the rarity 
of the disease, there have been few prospective trials of systemic therapy. In the 1970s 
and 1980s initial trials exploring cisplatin combination regimens were undertaken and 
the three-drug regimen of cisPlatin, doxorubicin (Adriamycin) and Cyclophasphamide 
(PAC) emerged as an active regimen with response rates of 50% or higher.2Cisplatin/
etoposide has published response rates over 50% from prospective studies.3 Even more 
aggressive and active four-drug regimens have also been explored with very high 
response rates, but no clear survival advantage. The activity of corticosteroids has been 
reported for thymoma in many anecdotal reports and small case series, but it is not clear 
that these are tumor responses. More likely these represent corticosteroid lympholytic 
activity. Hence, corticosteroids are generally not a primary component of therapy for 
this disease. When the same regimens studied in advanced disease are brought into the 
pre-surgery realm, the response rates remain high. The term “primary chemotherapy” 
is preferred in this setting per guidelines from the International Thymic Malignancies 
Interest Group (ITMIG).4According to ITMIG definitions “Primary chemotherapy is 
a chemotherapy delivered as first treatment in case of locally advanced nonmetastatic 
thymic tumor (Masaoka-Koga stage III or IVA)…. The main objective of primary 
chemotherapy is to make feasible subsequent R0 resection.” Trials in this setting are 
limited, small, accrue slowly and few are prospective. It is also difficult to compare 
across trials because invasive thymoma is a surgically staged disease and one cannot 
reliably assess stage prior to resection. Several very small (N<10) prospective trials with 
cisplatin/anthracycline combination regimens from the 1990s reported high responses 
and increased respectability of locally advanced disease, including one series of thymic 
carcinoma.5-7 A 100% response rate and 70% complete resection rate was reported in a 
slightly larger trial of 16 patients with the four drug ADOC regimen (PAC plus a vinca 
alkaloid).8The largest prospective trial comes from MD Anderson with 22 patients who 
all received a PAC variant with prednisone preoperatively, with a 77% response rate 
(14% complete response), over 75% complete resection rate and a 79% survival rate at 7 
years. Patients did receive adjuvant radiation and chemotherapy as well. More studies 
have continued to be small and often retrospective with similar chemotherapy regimens 
and responses in the 60-90% range.9, 10The use of steroids is variable in these studies. In 
case series that compared outcomes from different eras both prior to and after adoption 
of the use of primary chemotherapy, a survival benefit was realized for those patients 
treated with primary chemotherapy compared to surgery alone and R0 resection rates 
were higher, supporting this approach.11, 12 Though there is no one standard approach, the 
most common strategy for invasive thymoma and thymic carcinoma that is not readily 
resectable at presentation, is primary chemotherapy followed by resection followed by 
consideration of adjuvant radiation therapy. Most centers consider PAC the preferred 
regimen for patients able to tolerate it. The use of corticosteroids is controversial but may 
reduce tumor size due to lympholytic activity in patients with lymphocyte predominant 
disease. Novel agents will need to be explored in this setting to improve response and 
respectability rates and ultimately cure rates. There is an ongoing phase II clinical trial 
of cetuximab with cisplatin, doxorubicin, and cyclophosphamide in patients with locally 
advanced thymoma in the United States (NCT01025089) and it is hoped that other trials 
will follow. There is no proven role for the addition of pre-operative radiation therapy. 
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THE RATIONALE FOR THE ADDITION OF RADIOTHERAPY TO 
INDUCTION CHEMOTHERAPY FOR STAGE III THYMOMA
Robert J. Korst  
Daniel And Gloria Blumenthal Cancer Center, New Jersey/NJ/UNITED STATES OF 
AMERICA
Thymomas are rare tumors of the thymus gland which usually follow an indolent clinical 
course. Recurrence and survival following treatment are ultimately dependent on 
tumor stage, which is based on invasive characteristics. While stage I and II thymomas 
uncommonly recur, patients with stage III disease have a significantly higher chance 
of recurrence following resection, ranging from approximately 20-50%. In addition 
to tumor stage, recurrence and prognosis depend on the ability to perform a complete 
surgical resection, which has remained the cornerstone of management of thymomas. 
Unfortunately, complete resection is not possible in approximately half of patients 
with stage III disease. Published recurrence patterns following complete resection of 
thymomas demonstrate that the majority of recurrences occur in the pleural space or 
lung (in areas removed from the primary tumor site), followed by the mediastinum (local 
recurrence) and distant organ sites. Given the paramount role of complete resection 
in the management of thymomas, combined with the suboptimal resectability of stage 
III lesions, the ability to shrink lesions prior to attempted resection seems attractive. 
To this end, a small number of phase II clinical trials, as well as observational studies, 
have demonstrated higher resectability rates following induction chemotherapy for 
stage III tumors compared to historical controls. Radiographic response rates have been 
high in these series, and a small number of patients experienced a complete pathologic 
response to chemotherapy. A problem with this body of literature, however, is that 
selection criteria for induction chemotherapy are unclear, with many studies describing 
patients as simply being “unresectable”. Given a potentially promising effect of induction 
chemotherapy on resectability of stage III thymomas (with a minority of patients being 
“downstaged” to no viable tumor), the rationale exists to add an additional modality 
to induction chemotherapy with the aim of achieving even higher resectability and 
complete pathologic response rates. The achievement of a complete pathologic response 
is inherently attractive since experience with other thoracic cancers (e.g. lung and 
esophagus) has suggested that patients without viable tumor (or those downstaged) 
following induction therapy and resection have the highest survival advantage, 
implying that enhancing the response to an induction therapy regimen should be 
a priority. Evidence exists which suggests that the addition of radiation therapy to 
induction chemotherapy for stage III thymomas should be seriously investigated. First, 
thymomas are radiosensitive tumors. Older, small series of thymoma patients treated 
definitively with external beam radiotherapy (~40-60 Gy) have demonstrated combined 
radiographic partial and complete response rates well over 50%, with some series 
approaching 100%. These older series, however, had relied on plain chest radiograph for 
response assessment for many earlier patients evaluated prior to the advent of computed 
tomography. Despite this, contemporary series describe the use of radiotherapy alone 
in a preoperative setting, showing significant reductions in tumor size (measured using 
computed tomography) in the majority of patients using doses as low as 18-20 Gy. Given 
this radiosensitivity, the addition of radiotherapy to induction chemotherapy may have 
significant potential for enhancing the resectability of stage III thymomas. A second 
reason to consider adding radiation to induction chemotherapy for stage III thymoma 
is the potential to downstage the tumor and ultimately increase the rate of complete 
pathologic response prior to attempted resection. Although not directly compared in a 
randomized fashion, clinical trials evaluating induction chemoradiotherapy for locally 
advanced esophageal cancer consistently have higher rates of complete pathologic 
response when compared to trials which have evaluated induction chemotherapy alone, 
with complete responders clearly surviving the longest. In addition, potential benefits 
are seen in patients with locally advanced non-small cell lung cancer who receive 
induction chemoradiotherapy compared to chemotherapy alone. Once again, although 
directly compared, randomized data are sparse, patients participating in clinical trials 
with N2 disease who receive induction chemoradiotherapy tend to have higher rates 
of mediastinal downstaging compared to those enrolled in trials evaluating induction 
chemotherapy alone. Further, these downstaged patients tend to enjoy longer survival 
than those who are not downstaged. Further, the addition of thoracic radiotherapy 
to chemotherapy in the vast majority of these trials for lung and esophageal cancer 
appears to be tolerable. Given that thymoma patients tend to be younger than lung 
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cancer patients, and tobacco smoking and obstructive lung disease are not risk factors 
for thymoma, the addition of radiotherapy to chemotherapy in the induction setting 
should be tolerable for thymoma patients as well. Finally, given that the majority of 
recurrences of thymoma following complete resection occur distant from the radiation 
field (mediastinum), the use of routine adjuvant (postoperative) radiotherapy needs to 
be questioned. Since thymomas are so radiosensitive, patients with stage III disease may 
be better served if this modality is used in the induction setting, where the potential for 
benefit appears greater. Although the rationale for adding radiotherapy to induction 
chemotherapy for stage III thymoma seems straightforward, very little published data 
exist evaluating this strategy. To this end, a phase II, multi-institutional clinical trial has 
been ongoing using induction chemoradiotherapy (cisplatin and etoposide concurrent 
with 40-45 Gy) for patients with high risk thymoma confined to the mediastinum. This 
trial eliminates the subjective inclusion criterion of “unresectable” and instead accrues 
patients according to strict radiographic criteria. The primary endpoint is the rate of 
complete pathologic response, with secondary endpoints being the rate of complete 
resection, toxicity, the role of positron emission tomography in predicting stage and 
resectability, and recurrence rates/failure patterns. Initial results from this trial are 
expected to be available in 2013. 
Keyword: thymoma
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CLASSIFICATION OF THYMIC CARCINOMA
Alexander Marx1, Philipp Ströbel2  
1Department Of Pathology, University Medical Center Mannheim, University Of 
Heidelberg, Mannheim/GERMANY, 2Department Of Pathology, University Of 
Göttingen, Göttingen/GERMANY
Thymic carcinomas (TC) are a heterogenous group of thymic epithelial neoplasms 
with numerous variants, including squamous, clear cell, mucoepidermoid and 
neuroendocrine tumors. With the exception of squamous carcinomas (TSCC), the 
histology of most variants is not different from similar tumors in other organs, although 
the clinical background (e.g. frequent association of thymic neuroendocrine tumors 
with MEN-1) may differ. Histology is an important prognostic stratum in TC. Existing 
data suggest that the prognosis of TSCC and well-differentiated neuroendocrine tumors 
is considerably better than that of basaloid, lymphoepithelial and poorly differentiated 
neuroendocrine carcinomas. Genetic data have only been published for TSCC. 
The baseline here is that a) the supposedly “non-environmental” TSCC differ from 
“environmental” squamous cell carcinomas in other organs such as lung and head and 
neck, b) TSCC show recurrent genetic alterations (namely losses of chromosomes 1q, 
6q, 13q and gains of chromosome 1q, 17q and 18) and c) the genetic alterations found in 
TSCC are partially overlapping with B3 thymomas, but are generally more complex. TC 
as a group are 10 times rarer than thymomas. The distinction between the two groups is 
prognostically important (thymomas, in contrast to TC, usually do not metastasize to 
lymph nodes) and usually straightforward. However, the distinction between type B3 
thymoma and TSCC, G1 can be difficult and a small number of “grey zone” cases exist. 
In the vast majority of cases, however, overexpression of CD5, CD117 and absence of TdT 
positive immature T cells are reliable features of TSCC. CD117 (c-KIT) is interesting 
because it is strongly expressed in the vast majority of TC with squamous differentiation 
and is a potentially drugable target, although existing data suggest that only the few 
patients with c-KIT mutated tumors may benefit from respective treatments. However, 
the role of c-KIT (and other frequently expressed receptor tyrosine kinases, such as the 
EGFR) in the biology of TC is unclear and may merit further studies. Thymic squamous 
cell carcinomas have been shown to frequently express FOXN1, a transcription factor 
important for thymic organogenesis and, if deleted, responsible for the nude phenotype 
in mice. This finding is interesting since it raises the possibility that thymic carcinomas 
may be derived from a thymic epithelial progenitor cell. By gene expression analysis, 
we found that TSCC form a more homogeneous tumor group than B3 thymomas. In 
contrast, B3 are more heterogeneous and some cases show considerable kinship with 
type A thymomas. Compared to B3 thymomas, TSCC exhibited significant enrichment 
for DNA damage response genes and cell survival pathways. These results earmark 
major biological differences between B3 thymomas and TSCC. Under a translational 
perspective, these findings challenge therapeutic concepts that suggest similar adjuvant 
protocols for B3 thymomas and TSCC and, instead, underline the need to develop novel 
“targeted” therapies.
Keywords: thymic carcinoma, thymus, molecular biology
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CLINICAL AND BIOLOGICAL DIFFERENCE BETWEEN THYMO-
MA AND THYMIC CARCINOMA
Meinoshin Okumura  
Department Of General Thoracic Surgery, Osaka University Graduate School Of 
Medicine, Suita-city Osaka/JAPAN
Thymic epithelial tumors are categorized into thymomas and thymic carcinomas 
including thymic neuroendocrine tumors. Thymic epithelial tumors are well-known for 
variability in the histological appearance. Characteristics of thymoma in microscopic 
appearance is the organotypic nature suggesting the thymic origin. On the other hand, 
thymic carcinomas have microscopic appearances which are similar to malignancies 
in the other organs represented by squamous cell carcinoma. Here, I discuss clinical 
and biological difference between thymoma and thymic carcinoma. Thymic epithelial 
neoplasms are also heterogeneous in the biological function. Several studies have 
shown that thymomas possess CD4+CD8+ double positive T cells, which are the typical 
phenotype of cortex in the normal thymus. Especially, type B1 thymoma according 
to the World Health Organization pathological classification holds a number of 
CD4+CD8+ double positive T cells comparable to the normal thymic tissue. On the 
other hand, thymic carcinomas lack this lymphoid component. These observations 
suggest that thymomas have immunological function similar to the thymic cortical 
epithelium, while thymic carcinomas do not. Consistently with this function, thymomas 
are frequently associated with autoimmune diseases represented by myasthenia gravis 
although thymic caricinomas are not. Nearly 70% of thymomas appear as Masaoka 
stage I or II diseases while thymic carcinomas usually in advanced stages at the time 
of diagnosis. Swelling of lymph node suspective of nodal metastasis strongly suggest 
thymic carcinoma. Furthermore, PET-CT has been shown to be helpful in differentiation 
between thymoma and thymic carcinoma, and thymic carcinomas often express more 
than 6 of SUVmax while it is usually less than 6 in thymomas. Owing to the indolent 
nature of thymomas, palliative resection contributes to relatively long-term survival 
in Masaoka stage III and IV cases. In stage III thymoma with involvement of the great 
vessels, subtotal resection combined with chemotherapy and radiation therapy can be 
justified. In stage IVa thmoma with pleural dissemination, resection of the primary 
tumor and pleural lesions possibly results in long-term survival. In contrast to thymoma, 
subtotal surgical resection does not have any impact in the treatment of thymic 
carcinomas. Finally, tumor death occurs even after 10 years after resection in thymoma 
patients while all the tumor deaths were seen within 5 years after resection in thymic 
carcinoma patients. All these facts indicate that thymomas are bilogically functional and 
less oncologically aggressive compared with thymic carcinomas. Thymomas and thymic 
carcinomas, therefore, are considered as different diseases and the treatment strategy 
should be determined according to the stage as well as the pathological diagnosis. In 
some type B3 thymomas, however, we observed areas which lack CD4+CD8+ double 
positive T cells and resemble squamous cell carcinoma. Thus, type B3 thymoma and 
thymic carcinoma are sometimes difficult to separate. Although thymoma and thymic 
carcinoma should be treated as different tumors in general, transition from type B3 
thymoma to squamous cell carcinoma following accumulation of genomic imbalance 
and mutations might be present.
Keyword: thymic epithelial tumor
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THE ROLE OF RADIATION THERAPY IN THYMIC MALIGNAN-
CIES INCLUDING THYMIC CARCINOMA
Ritsuko Komaki, Daniel R. Gomez  
UT MD Anderson Cancer Center, Houston/UNITED STATES OF AMERICA
Although the predominant approach in the treatment of thymoma and thymic 
carcinoma is surgery, radiation therapy also has an important role, either as 
postoperative therapy to reduce the risk of mediastinal recurrence or as part of definitive 
treatment for patients that who cannot undergo surgery for medical reasons, for locally 
advanced disease, or for tumors that remain unresectable after induction chemotherapy. 
We present here a review of radiation therapy for thymic malignancies and briefly 
discuss the potential benefits from novel technologies for such treatment. Thymic 
carcinoma is rare, but more aggressive tumor which has tendency to fail locally and 
distantly. Thymic carcinoma has more frequent EGFR and/or HER2 abnormalities 
compared to thymoma. The outcome of thymic carcinoma is usually worse than invasive 
thymoma. Postoperative Radiation Therapy: Indication R0 (Completely Resected) 
Thymic Malignancies In general, radiation should be considered more strongly as the 
risk of recurrence increases. Therefore, for patients with the lowest likelihood of 
recurrence (i.e. completely resected Masuoka stage I thymoma), radiation can be safely 
omitted. For those at intermediate risk of local recurrence after complete resection, i.e. 
those with aggressive tumor histologies (such as thymic carcinoma) or Masaoka stage II 
and stage III disease, retrospective evidence exists both to support and contradict claims 
of benefit from adjuvant radiotherapy after complete resection. In general, our 
institutional practice includes postoperative radiation for completely resected Masaoka-
Koga stage III thymoma and stage II or III thymic carcinoma. Risk assessment and 
stratification is usually done in a multidisciplinary setting and drives the choice of 
adjuvant treatment. Prospective trials, which would require multicenter collaboration to 
obtain adequate patient accruals, would be invaluable in establishing the role of 
postoperative radiation in thymic malignancies. The International Thymic Malignancy 
Interest Group published a set of definitions and reporting guidelines for the use of 
radiation therapy for thymic malignancies in 2011. Pertinent recommendations for 
postoperative therapy are as follows. First, the term “postoperative” should be used for 
situations in which the tumor is resected and no residual disease is evident on imaging. 
If gross disease is present on postoperative imaging, then the disease should be defined 
as “recurrent” and the intent as “radiation for postoperative disease.” Second, the 
minimum acceptable dose for postoperative R0 disease is 50 Gy in 5 weeks. Third, the 
treating physician should specify several aspects of the radiation, including the 
prescription dose, fraction size, dose to the initial field, and boost fields if they are to be 
used. Finally, radiation to elective nodal regions not recommended because of the rarity 
of their involvement, and the extent of malignancy before surgery should be used as a 
guide for designing the treatment fields. Microscopic Positive Margins (R1) and Gross 
Disease (R2) Radiation for R1 or R2 thymic malignancies, like that for completely 
resected disease, should be started within 3 months of surgical resection. Input from 
surgeons, radiologists, and pathologists is especially helpful in assessing the regions at 
highest risk of recurrent disease. In the ideal case, clips will have been placed at the time 
of surgery delineating such regions for the treating radiation oncologist. The 
International Thymic Malignancy Interest Group guidelines state that doses between 40 
Gy and 64 Gy are most appropriate for microscopically positive margins, whereas doses 
of 54 Gy or higher dose should be used for gross disease; both should be given in 
standard fractions of 1.8- to 2.0-Gy. Patients with positive margin need to receive 
concurrent chemotherapy and radiotherapy especially among patients with thymic 
carcinoma if patients can tolerate. Definitive Radiation Therapy Because surgical 
resection is the preferred method of definitive local treatment, definitive radiation 
therapy is generally used for patients who are not candidates for surgery because of either 
the extent of disease at diagnosis or medical comorbidities. Because chemotherapy is a 
known radiation sensitizer, and thymic carcinoma is typically a chemosensitive disease, 
the combination of chemotherapy and radiation is considered most likely to control 
disease in these circumstances. In prospective trials of multimodality therapy for 
inoperable disease, treatment regimens have usually involved combinations of cisplatin-
based chemotherapy with radiation. In this setting, which is analogous to recurrent 
disease after surgical resection, we recommend radiation doses of 60 Gy -66 Gy to 
encompass gross disease plus a margin for microscopic regions at risk, and we consider 
hemithoracic radiation to be investigational. Thymic carcinoma behaves more non-small 
cell lung cancer arising from the thymus. Therefore, unresectable thymic carcinoma 
needs to be treated based on the histology or molecular biomarkers e.g. EGFR, HER2 
c-KIT and BCL-2 expression. Approximately 50% of thymic carcinoma has squamous 
histology which can be treated with cisplatin based chemotherapy and radiotherapy. If 
the unresectable thymic carcinoma has atypical carcinoid histology, etoposide and 
cisplatin and radiotherapy might be the best option. For the recurrent thymic carcinoma, 
molecular targeted agents e.g EGFR-TKI, c-KIT inhibitors and VEGFR inhibitors can be 
tried on certain protocol setting with or without radiotherapy. Techniques Because of the 
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central location of thymic malignancies and the relatively high doses used in radiation 
therapy, we strongly recommend the use of highly conformal techniques, such as three-
dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation 
therapy (IMRT), or, if available, proton beam therapy. Numerous studies of lung cancer 
have shown the value of dose-volume histogram analysis for estimating doses to normal 
structures, and of using multiple beam angles to enhance conformality, in terms of 
greater sparing of intrathoracic organs, which in turn leads to better outcomes. In 
addition, accounting for the internal motion of the tumor through the use of 4D 
treatment planning, in which respiration and variations in target volume based on the 
natural respiratory phases are measured, also offers both dosimetric benefit and, when 
combined with IMRT, clinical improvements as compared with the use of 3D-CRT. 
Proton beam therapy can offer still greater advantages over photon-based techniques 
owing to the physical properties of the particles (i.e., the Bragg peak), which produce 
lower doses both proximal and distal to the target volume. Finally, because tumors can 
show substantial changes in shape or size over the course of several weeks of radiation 
therapy, we recommend that when radiation is to be used as definitive therapy, adaptive 
planning should be considered, meaning that additional CT scans be obtained at 
approximately halfway through the treatment period to assess if the treatment plans 
should be modified. Long-Term Consequences of Radiation on the Heart and 
Vasculature Abundance evidence exists to show that long-term survivors of mediastinal 
radiation therapy can develop both acute and chronic cardiac sequelae. With regard to 
acute effects, the dose and fractionation of the radiation and the volume of heart 
irradiated all affect the risk of pericarditis and pericardial effusion. Given the close 
physiologic association between perfusion and ventilation, one might expect that 
radiation to the heart could affect lung function and vice versa. In a clinical study, 
investigators found that several heart dose-volume variables predicted radiation 
pneumonitis and that the fit of a model predicting pneumonitis was improved by the 
incorporation of heart variables. In conclusion, considerable evidence has shown that 
irradiation of the heart and vasculature can lead to increased acute and long-term 
toxicity and that these side effects are related to the dose, volume, and exact location of 
the irradiated field. Short-term surrogates of long-term toxicity such as findings on 
cardiovascular imaging or biomarker correlates would be helpful for identifying which 
patients at greatest risk for cardiac events. In the meantime, we recommend the 
continued use of advanced radiation therapy technologies such as IMRT, proton beam 
therapy, 4D imaging and treatment planning, and adaptive planning whenever possible 
to minimize the dose to mediastinal structures for patients with thymic disease, many of 
whom will survive for several decades and thus will live to see the long-term 
consequences of irradiation of these vital organs.
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CHEMOTHERAPY FOR THYMIC CARCINOMA
Kiyotaka Yoh  
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Thymic carcinoma is recognized as a distinct entity from thymoma in thymic epithelial 
tumors. Complete surgical resection is the preferred treatment to achieve cure. However, 
thymic carcinoma tends to behave in a malignant manner clinically, and in many cases 
dissemination or distant metastasis has already occurred at presentation. Patients 
with metastatic or recurrent tumors are candidates for systemic chemotherapy, but 
no standard chemotherapy regimen has been established because of the rarity of this 
tumor. A review of the literature on chemotherapy for advanced thymic carcinoma was 
performed. The previous reports consisted of subset analysis of thymic carcinoma in 
prospective trials for thymoma and thymic carcinoma and retrospective case series that 
evaluated chemotherapy for only thymic carcinoma. Most of chemotherapy regimen 
evaluated in thymic carcinoma had included platinum and anthracyclines similar 
to that in thymoma. First-line platinum-based chemotherapy had response rates of 
22–75% although the number of patients was small. No prospective randomized trial of 
chemotherapy regimens has been performed. The use of molecularly targeted therapy for 
the treatment of thymic carcinoma has recently been reported such as prospective trials 
of imatinib.Most of chemotherapy regimen evaluated in thymic carcinoma had included 
platinum and anthracyclines similar to that in thymoma. First-line platinum-based 
chemotherapy had response rates of 22–75% although the number of patients was small. 
No prospective randomized trial of chemotherapy regimens has been performed. The use 
of molecularly targeted therapy for the treatment of thymic carcinoma has recently been 
reported such as prospective trials of imatinib. Some platinum-based chemotherapy for 
advanced thymic carcinoma shows modest activity. More research on optimal systemic 
chemotherapy for thymic carcinoma would appear to be necessary.
Keywords: platinum, thymic carcinoma, anthracycline, chemotherapy 
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ROBOT-ASSISTED THORACOSCOPIC SURGERY FOR THYMIC 
DISEASE – EFFICACY AND CURRENT CONTROVERSIAL  
PROBLEMS
Hiroshige Nakamura  
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Background: Robot-assisted thoracoscopic surgery (RATS) has infiltrated our general 
thoracic field. The great advantage of robotic operation is the accurate manipulation by 
articulated robotic forceps under three-dimensional vision. The aim of this study was 
to investigate the efficacy and clear up the controversial problems of RATS for thymic 
disease. Materials and Methods: We have experienced 13 patients who underwent RATS 
for thymic disease since January 2011. Operation was performed in the supine position 
under general anesthesia with separate ventilation by using CO2 insufflation into the 
thoracic cavity at the pressure of 5 to10 mmHg. We used da Vinci S surgical system 
(Surgical Intuitive, Inc., Mountain View, CA, USA) with 3 arms driving in from the 
tumor existed side (right side 8 cases, left side 5 cases). Four port incisions were made. 
A 30-degree endoscope was introduced through the fourth intercostal space along 
the anterior axillary line. Typically, the left and right robotic arm ports were placed 
in the second or third and seventh intercostal spaces around the mid-clavicular line 
respectively and the assist port was made through the sixth intercostal space along the 
mid-axillary line. Cadiere forceps were attached to the robot’s left arm, which was mainly 
used to grasp the tissue. Dissection was usually performed with a robotic spatula cautery 
on the right arm. There were 4 males and 9 females with a mean age of 51.8 years (range 
18-78 years). Six patients suffered from myasthenia gravis (MG). Other diseases were 
thmoma, Castleman disease, mature teratoma and thymic cyst. In 6 cases of thymoma 
operated by RATS, we analyzed perioperative parameters, especially comparing with 
15 cases by video-assisted thoracoscopic surgery (VATS) and 17 cases by thoracotomy 
for thymic tumors which were operated since 2005. Results: Perioperative parameters 
for 13 thymic disease were as follows: mean operation time 213.5min, console time 
155.1min, amount of bleeding 8.3g, duration of drainage period 3.0days (1.2 days except 
chylothorax) and postoperative hospital stay 7.4 days (5.8 days except chylothorax). There 
were no conversions to open surgery. Postoperative complications occurred in only one 
patient who developed chylothorax for MG (MGFA4b) with invasive thymoma operated 
with combined resection of phrenic nerve and improved by conservative therapy in 24 
days after operation. There were six cases of thymoma operated by RATS. Table 1 shows 
the perioperative parameters in three groups. In thoracotomy group, there were large 
proportions of male patients, bigger tumors, invasive tumors and thymic cancer. RATS 
group showed smaller amount of bleeding in spite of being operated larger tumor as 
compared with VATS group. 
Discussion: Since RATS for thymic disease was reported, there have been a lot of 
discussions from various viewpoints. Especially, it has been a very important issue to 
evaluate the efficacy of RATS in comparison with both thoracoscopic and open surgery. 
According to the literature and also my operative feelings, one of the greatest advantages 
of RATS for thymic disease must be comfortable maneuverability with articulating 
robotic forceps in the restricted area of anterior mediastinum. By these reasons, it 
might be a rather preferable to resect a larger thymoma by RATS than VATS. On the 
other hands, the robotic vision made by the fixed camera position sometimes produces 
a blind spot in the operative field. Of course, although three-dimensional scope view 
improves such problems, we always have to carefully manage the camera position and 
appropriately switch the angle of 30-degree oblique camera up and down. Recent study 
also described the superiority of RATS for MG in the remission rate as compared with 
VATS. These results must be also re-investigated in Japan. RATS for thymic disease will 
be very attractive and feasible for general thoracic surgeon and so, it is expected that 
we must quickly discuss about trocar replacement, operative technique, perioperative 
management and also coverage of medical insurance to establish this new technology. 
Conclusion: Although we have experienced a small series, RATS for thymic disease 
provided us a comfortable operation with accurate manipulation. Especially, dexterity 
of articulated robotic forceps showed a great efficacy in the operation of thymic tumor. 
At the present time, RATS wouldn‘t have still enough evidence to be established as a 
standard operation for thymic diseases. So, we have to continue to evaluate the several 
benefits of RATS for thymic disease both technically and therapeutically. A longer 
follow-up is necessary to verify long-term clinical results. 
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Introduction: During the last decade minimally-invasive thoracic surgery after some 
doubt and criticism in the beginning was acknowledged and further developed. The 
latest step in this development is robotic-assisted surgery representing by principle a 
new quality. In the narrow space of the mediastinum different aspects support the use of 
3-dimensional view for the surgeon, articulated instrument tips, and the stable camera 
position conducted by the surgeon. Other general aspects are smallest movements 
at the trocar entrance sites leading to lowest pain and best cosmesis for the patient. 
Furthermore, robotic surgery permits highest ergonomic standards even with unusual 
trocar or patient positions by the technique of master-slave system with the surgeon’s 
console. For any new surgical technology the aspects of learning and training as well as 
the degree of dexterity are important. Robotic assistance has been repeatedly shown to 
be connected with a faster learning curve in prospective randomized trials comparing 
non-robotic and robotic surgical work. In addition, lower experience in minimally-
invasive surgery was a lower barrier for learning robotic surgery. The dexterity to be 
obtained with this technology meets highest requirements. The indication of myasthenia 
gravis requires radical resection of all visible and potential ectopic thymic tissue. 
Therefore, the traditional mediastinal area of resection is between thyroid gland and 
diaphragm and between both phrenic nerves, respectively. But very often these margins 
have to be extended for example due to the tissue in the aorto-pulmonary window or 
in the aorto-caval groove. The most frequent tumor of the anterior mediastinum is 
thymoma, which represents an absolute indication for surgery. The standard of surgical 
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treatment is a radical thymectomy due to oncological rules. In about 15-30 % of all cases 
with myasthenia gravis, a thymoma is found whereas 30-50 % of patients with thymoma 
develop myasthenia gravis. The indication of thymectomy for patients with non 
thymoma myasthenia gravis is relative, due to the lack of comparative approval. Even 
today in many centres for both indications open surgery through median sternotomy 
is still the established procedure. However, currently there is a variety of up to 14 
different surgical approaches for thymectomy. A sharp increase of centres performing 
minimally- invasive thymectomy, and especially robotic-assisted thymectomy, illustrates 
the search for the optimal technique. The evaluation of the technique is still made 
difficult by the low average number of thymectomies per centre and the necessity of 
validated parameters for the improvement of myasthenia gravis and the outcome after 
thymectomy for thymoma. Methods: A literature analysis evaluated the arguments 
for minimally-invasive thymectomy versus conventional surgical approaches. The 
special reasons for starting a robotic thymectomy program are summarized from 
the literature as well. A prospective clinical study analysed 295 consecutive robotic 
thymectomies (1/2003 – 08/2012, age range 4-86). A standardized procedure was 
developed for robotic thymectomy prefering the left unilateral 3-trocar approach with 
the da Vinci robotic system (Intuitive Surgical, Sunnyvale, California). All patients with 
myasthenia gravis were analysed for improvement of the disease and morbidity of the 
procedure (quantification according to the Myasthenia Gravis Foundation of America 
classification). With respect to mediastinal tumors the advantages of robotic dissection 
were analysed. Inclusion criteria were suspicion of thymoma, clinical estimation of 
resectability with clinical stage I or II (according to Masaoka-Koga classification). 
Possible extension of selection criteria and oncological completeness of resection was 
determined. The well defined outcome parameters for thymoma were used for a single 
centre series of 55 thymomas and a European multicentre retrospective study of 79 
thymoma patients. Results: In a mixed population with myasthenia gravis and/or 
thymoma the exclusion rate was very low. In particular, there was no limit as to body 
mass index, position or size of thymic tumour per se. The operation time was between 
1 and 3 hours with a conversion rate of below 3%. There was no operative mortality and 
a morbidity rate of 1.7%. The most frequent indication was generalized seropositive 
myasthenia gravis. The amount of tissue resected and the specimen size were measured 
and documented pointing to the extent of dissection. In this group of patients the 
most frequent finding was follicular hyperplasia of the thymic gland. The cumulative 
rate of complete remission of myasthenia gravis was 43%. For thymoma a right-sided 
approach was employed in case of predominant right position of the thymoma. In a 
small number of patients, extension of the approach by contralateral robotic dissection 
or contralateral thoracoscopy (hybrid procedure) was necessary. In the single-centre 
series no recurrence was found until now. There was no thymoma-related mortality. The 
international European combined experience had very similar results. Conclusions: 
With different degree of approval the following arguments support the use of robotic 
technology for thymectomy (as compared to non-robotic thoracscopic approach): 
stratified learning program with systematic increase of skills and stepwise takeover 
of operations due to the dual console system, shorter learning curve, best standard of 
visualization of the operation field, ergonomic and convenient working conditions 
for the surgeon due to most suitable instruments with intuitive use of the wristed 
instrument tips. The advanced technology for mediastinal dissection might translate 
in increased radicality and, therefore in better results of improvement of myasthenia 
gravis in a mixed series including the difficult cases. For thymoma robotic assistance also 
allows better oncological “no touch“ dissection technique . Therefore, in a mixed series 
of thymectomies a very low conversion rate could be obtained. The robotic approach can 
always be extended by a cervical approach, in form of bilateral procedure or as hybrid 
procedure with contralateral thoracoscopic approach. The results of a large single-centre 
experience of almost 300 thymectomies have been supported by a multi-institutional 
analysis for thymoma. Robotic technology seems to have a larger potential for new 
advantages as compared to non-robotic minimally-invasive surgery. Especially robotic 
surgery has led to an increased acceptance of thymectomy. 
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The open surgery using either median sternotomy or thoracotomy has been a 
standard approach for the resection of thymoma. Minimally invasive surgery using a 
thoracoscopy system has been introduced for the last two decades, and several reports 
suggested that thoracoscopic thymectomy provides the comparable surgical outcomes. 
More recently, a new tool (the da Vinci Surgical System, Intuitive Surgical, Sunnyvale, 
CA, USA) is available and used in various fields of surgery, mainly in urology. A robotic 
system provides a high-definition, magnified view with three-dimensional image, and 
instruments that are offering surgeons up to 7 degrees of freedom. It is logical that this 
inherent advantages allow surgeons to do more precise and secure surgery than ever 
before. However, we need a process of verification in terms of its necessity, safety, and 
cost-effectiveness before we accept new technology as a standard treatment. 
 
[1] Is a robotic system necessary for the resection of thymoma? 
A 3-dimensional vision and an increased dexterity are the major advantages of robotic-
assisted surgery. Owing to these advantages, it is possible to create an anastomosis in a 
narrow operating field, and to dissect lymph nodes along specific nerves without injury 
to them. It means that a robotic-assisted surgery offers its maximal performance when 
it is applied to the complex procedures within a single-quadrant. Robotic-assisted 
laparoscopic radical prostatectomy (RALP) is a good example, and RALP has been 
widely accepted as one form of standard treatment for prostate cancer. A dissection of 
lymph nodes along recurrent laryngeal nerve for esophageal cancer is also facilitated 
when a robotic system is applied to video-assisted thoracic surgery (VATS) system. 
However, most of thymomas are found in anterior mediastinum which is a relatively 
wide space as compared to retropubic or left paratracheal area. For stage I-II thymomas, 
we can resect them with no such difficulty by VATS because the operating field is 
wide, and it doesn’t need any complicated procedures. For stage III thymomas, open 
surgery is recommended to ensure R0 resection, but the resection and reconstruction of 
pericardium or the wedge resection of lung tissue can be done by VATS in selected cases. 
Robotic-assisted surgery seems to have no added benefit in the resection of thymoma. 
 
[2] Can it provide better surgical outcome than thoracoscopic thymectomy? And is it a 
safe oncological procedure? 
There have been many reports which showed better surgical outcomes of VATS 
thymectomy(VATS-T) in terms of surgical complications, bleeding amount, and pain 
scores etc., as compared to open thymectomy. In a robotic-assisted thoracoscopic 
thymectomy (RATT), the number and position of trocars are similar, and basic 
procedures are nearly same with VATS-T. Although RATT offers intrapleural 
articulation of the instruments, postoperative pain seems to be unchanged due to a 
small thoracotomy for a retrieval of the specimen. Regarding oncological outcomes, we 
can expect that long-term survival after VATS-T is comparable to that of open surgery 
when R0 resection is achieved. In RATT, there is a possibility of disruption or tumor 
spillage during manipulation because robotic system cannot provide a tactile feedback. 
Considering that thymoma is an indolent tumor, 10-year survival is required to assess 
the oncological outcome, and there has been no such long-term data in RATT because it 
was applied recently. 
 
[3] Can the current health system accept it as a standard treatment for thymoma? 
Introduction of a new technology must include a cost-benefit analysis. When it is 
beneficial for the health and is cheaper, the technology is easily accepted. Alternatively, 
when it is more expensive and worse in the health effect, the treatment will be discarded. 
When the new technology is more expensive but better, then acceptance depends on the 
willingness of each health system to pay the extra cost for the benefit. As for RATT, both 
the initial installation cost and the maintenance fee are much higher than VATS system, 
and it is unlikely that the costs will be decreased because of the monopoly of Intuitive 
Surgical. In our country, a cost for RATT is 3 times higher than a cost for VATS-T. Given 
that there is no absolute advantages of RATT over VATS-T, we cannot recommend our 
patients to pay additional thousands dollars for unclear benefits. 
 
Robotic-assisted surgery is a technical evolution of conventional thoracoscopic surgery, 
and has its inherent advantages. The current major drawback is the cost, and this 
new technology should be reserved for more complex procedures such as superior 
mediastinal lymph node dissection in esophagectomy etc, but not for the resection of 
thymoma. Only a randomized trial which compares RATT with VATS-T can answer the 
questionable benefits of RATT over VATS-T.
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Background: The accuracy of a three-dimensional robotic assisted videothoracoscopic 
approach, may favor a radical resection of thymomas. The aim of this study is to report 
the 8 years experience of a single referral centre in surgical treatment of thymomas with 
the policy to start any procedure with a robotic approach. Methods: We retrospectively 
analyzed all consecutive patients who underwent a thymectomy from April 2004 to 
April 2012 for a thymoma. The Da Vinci Robotic System was used by a 3 port, right-
sided approach. We analyzed the procedure time, morbidity, mortality, conversions, 
hospitalization, overall and disease free-survival. Results: 37 patients (22 females, 15 
males) with a mean age of 57.3 years (range 27-88 years) underwent a thymectomy 
using the Da Vinci Surgical Robotic System. 28 patients (75.6%) were diagnosed with 
myasthenia gravis. The preoperative CT scan showed in 91.1% of the patients suspicion of 
a thymoma. No biopsies were taken to confirm the diagnosis. The median time between 
onset of myasthenia gravis and the procedure was 12 months (range 0-72 months). 
Histological analysis revealed 37 thymomas; 3 type A, 7 type AB, 7 type B1, 14 type B2, 
4 type B3, and 1 thymus carcinoma. The Masaoka Stages were: I in 20 cases, IIA in 5 
cases, IIB in 8 cases, III in 3 cases and IVb in one case. The mean overall procedure time 
was 149 minutes (range 88-353 minutes). No surgical mortality was reported and there 
were no complications during the procedure. No conversions were needed for surgical 
complications. In four cases a conversion was preferred by the surgeon because tumor 
invasion in greater vessels was suspected. In one case a mini thoracotomy was performed 
at the end of the procedure because of the size of the tumor. Two patients (5.4%) 
suffered from a myasthenic crisis postoperative and required prolonged mechanical 
ventilation. One patient (2.7%) underwent a procedure for a thoracic herniation. Minor 
complications occurred in 3 patients (8.1%), in two patients due to pleural effusion and 
in one patient due to pneumonia. The median hospitalization was 3 days (range 3-25 
days). 17 patients (46%) underwent adjuvant radiotherapy. We started our follow-up 
at 12 months. The follow-up analysis with a mean of 40 months (range 14-79 months) 
showed a relapse in 1 patient. All patients were alive. The patients with a follow-up of 
less then 12 months were also all alive. Conclusion: The Da Vinci Robotic System is 
safe for thymectomies in patients with early and late stage thymomas. For late-stage 
thymomas an initial approach with the Da Vinci Robotic System may help to dissect the 
thymoma and visualize areas of tumor invasion to facilitate a subsequent thoracotomy 
or sternotomy.
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During the development in the thymus, a virgin repertoire of diverse TCR-ab 
recognition specificities in immature T cells is selected through positive and negative 
selection to form an immunocompetent and self-tolerant repertoire of mature T cells. 
Positive selection supports the survival of T cells that receive weak signals of low-affinity 
TCR engagement, whereas negative selection deletes potentially harmful self-reactive 
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T cells upon high-affinity TCR engagement. Recent advances in the biology of thymic 
stromal cells have indicated that proximal interplays among developing T cells, dendritic 
cells, and thymic medullary epithelial cells that promiscuously express tissue-specific 
self-antigens is essential for the establishment of a self-tolerant TCR repertoire. It 
has also been indicated that the formation of an immunocompetent TCR repertoire 
requires positive selection by thymic cortical epithelial cells that express unique protein 
degradation machineries including the b5t-containing thymoproteasome. These results 
suggest an essential role of self-peptide repertoires specifically expressed by multiple 
thymic microenvironments in the development of adaptive immune system.
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Tumors develop as a result of accumulation of alterations that are faithfully inherited upon 
somatic cell divisions, namely mutations and epigenetic alterations. Epigenetic alterations 
consist of alterations of DNA methylation and histone modifications. Although epigenetic 
alterations were presumed similar to mutations at the dawn of the cancer epigenetics 
era, their unique characteristics compared with those of mutations are now recognized, 
including the high frequency in tumors, high levels of accumulation in non-tumorous 
tissues, target gene specificity, and potentially reversible nature [Ushijima, Cancer Sci, 
101:300, 2010]. These characteristics of epigenetic alterations are leading to their unique 
use as diagnostic and therapeutic targets. High levels of aberrant DNA methylation are 
accumulated in normal-appearing gastric mucosae of people with Helicobacter pylori 
(HP) infection, and the methylation level is associated with gastric cancer risk [Maekita, 
Clin Cancer Res, 12:989, 2006; Nakajima, CEBP, 15:2317, 2006]. Similar findings have 
been reported in the liver, colon, breasts, and kidneys, and now an “epigenetic field for 
cancerization (an epigenetic field defect)” is considered to be present in a broad range of 
tumors. Especially in the stomach, we isolated marker genes that can distinguish gastric 
cancer patients among individuals with past HP infection with odds ratios of 12.7-36.0 
[Nanjo, Gastric Cancer, online]. The degree of epigenetic field defect is likely to be utilized 
as a tumor risk marker that reflects past exposure to various carcinogenic factors. As 
inducers of epigenetic alterations, aging and chronic inflammation are known. Using 
Mongolian gerbils infected by HP, we showed that chronic inflammation, not HP itself, was 
critical for methylation induction [Niwa, Cancer Res, 70:1430, 2010]. In contrast, repeated 
acute inflammation by a high concentration of NaCl or alcohol did not induce aberrant 
methylation [Hur, Carcinogenesis, 32:35, 2011]. Expression levels of Il1b, Tnfa, and Nos 
correlated with the degree of methylation induction. In a mouse colitis model induced by 
dextran sulfate sodium (DSS), methylation was induced even in SCID mice that lack T and 
B cells, suggesting the importance of macrophage-derived signals [Katsurano, Oncogene, 
31:342, 2012; Ushijima, Clin Cancer Res, 18:923, 2012]. In contrast with aberrant DNA 
methylation, alterations of a histone modification, H3K27me3, were induced as early as two 
weeks after DSS treatment. Some of them were carried over into colon tumors, and others 
led to induction of aberrant DNA methylation [Takeshima, in revision]. Taken together, 
chronic inflammation is considered to induce H3K27me3 alterations even in its early 
phase and to put a mark on some genes to become DNA methylated. DNA methylation 
is considered to be then induced in the marked genes and inherently susceptible genes 
[Takeshima, Epigenetics, 5:89, 2010], producing an epigenetic field defect. Epigenetic 
alterations are now one of the central players in translational cancer research. 
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REPORT OF ITMIG DATABASE - EUROPE
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Advancements in thymic malignancies have been slow so far, due to the rarity of the 
condition and the lack of coordination among those centers which have sufficient 
experience to provide consistent results. In an era of globalization and ease of 
communication there is no excuse against the lack of cooperation which has occurred 
so far. In the past decade, the most important thoracic societies addressed this issue by 
promoting dedicated thymic groups. In 2010 the International Thymic Malignancies 
Interest Group (ITMIG) was officially constituted, supported by the most representatives 
medical and surgical societies around the globe. In Europe, the European Society 
of Thoracic Surgeons (ESTS) thymic working group launched in 2011 the ESTS 
retrospective dataset project to collect retrospectively all thymic malignancies among 
its members. As of December 2011 a total of 36 centers joined the project and provided 
their data to the ESTS thymic working group. Overall, a total of 2151 patients were 
available for analysis. The patient population covered a 20-year period from 1990 to 2010. 
Among these patients, there were 1904 thymomas, 204 thymic carcinomas (TC) and 43 
neuroendocrine thymic tumors (NETT). 1768 patients (82%) had a complete resection 
(R0). Three outcome measures were employed according to ITMIG’s recommendations, 
overall survival (OS), disease-related survival (DRS) and freedom-from-recurrence 
(FFR) (the last for R0 resections). Survival analysis using DRS and FFR was undertaken 
using a competing risk model to take into account competing risks for the different 
events of interest. 2030 patients were analyzed for OS; 1330 patients were analyzed for 
DRS and FFR. The following covariates were analyzed: age, sex, Myasthenia Gravis, 
T size, Masaoka Stage, Diagnosis (thymomas by WHO histology, thymic carcinomas 
and NETT), administration of induction and adjuvant therapies, R status, year of 
intervention (1990-1995 (ref), 1996-2001, 2002-2007, 2008-2010), mean No. of patients 
provided by the centers (<=4 (ref), 5-9, >=10). Management of missing data and 
heterogeneity among centers were handled with specific statistical techniques (multiple 
imputation data and Cox’s shared frailty models). The analysis of the data is currently 
in progress but the results on such a large patient population, although with the limits 
of a retrospective dataset will be of help to elucidate many aspects in the management 
of thymic malignancies and may provide material to IASLC for the implementation of a 
consistent staging system for thymic malignancies expected in the next few years.
Keywords: thymoma, ESTS, thymic carcinoma, working group
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The Masaoka classification is now the most widely accepted and is an excellent predictor 
of the prognosis of thymoma. However, several articles have pointed out problems and 
have suggested that an update of the system is desirable. In order to collect reliable 
and large-scale clinicopathological and prognostic data of thymic epithelial tumors, 
ITMIG has chosen to use the Masaoka-Koga stage classification system. The definitions 
adopted by ITMIG defined precisely what constituted mediastinal pleural or pericardial 
involvement, and required that macroscopic suspicion of involvement should be 
confirmed microscopically for pathologic stage. The ITMIG is currently engaged in the 
development of a validated formal stage classification system for thymic malignancies, 
together with the IASLC and under the auspices of the UICC and AJCC in preparation 
for the next edition of the international tumor staging manuals in 2017. The Japanese 
Association of Chest Surgery (JACS) had collected the data of thymic epithelial tumors 
from all over Japan in 2000, based on the 1320 patients who had been surgically treated 
between 1990 and 1994. These data had been reported in 3 English manuscripts (Ann 
Thorac Surg 76:878-85, 2003. Ann Thorac Surg 76:1859-65, 2003. J Thorac Oncol. 5:S352-
6, 2010). In order to establish the Japanese database of thymic epithelial tumors, Japanese 
Association for Research of the Thymus (JART) accepted to consider the database project 
as an official project of JART. In the beginning of this year, we obtained the Institutional 
Review Board (IRB) approval from Osaka University Hospital to serve as the data 
office, and announced kick-off of the database project at the annual meeting of JART in 
February, 2012. The project was uploaded in the website of JART then. We set the dead 
line of collecting database in the end of July. Finally, 41 institutes are supposed to work 
for the project. We are planning to analyze more than 3,000 cases of thymic epithelial 
tumors in Japan. We are going to present the results at ITMIG 2012 in November.
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One of the principal goals of ITMIG is the collection of high-quality data on thymic 
tumors from its members around the world in order to foster collaboration across 
continents among interested clinicians and researchers. In doing this we hope to improve 
our understanding of the treatment and outcomes of these rare tumors. To accomplish 
this ITMIG has created an international database, accessible by the web, to collect both 
existing retrospective data as well as prospective collection of data on newly enrolled 
patients on an ongoing basis. This presentation will detail the development of this project 
and the collaboration between ITMIG and Purdue University in the genesis of the 
ITMIG-HUB. This is a web-based platform through which collective de-identified data 
can be securely stored, viewed, queried and analyzed. In addition, the HUB platform 
allows for educational modules, linkage to virtual tumor bank, and radiographic image 
storage and viewing. The Retrospective database aims to compile pre-existing data on 
patients with thymic neoplasms from ITMIG members around the world. One of the 
primary goals of this data collection will be to inform the development and validation 
of a staging system in conjunction with the International Association for the Study of 
Lung Cancer (IASLC). Regional societies in Europe and Asia have assisted in this effort 
by coordinating data collection among their respective members, greatly expediting 
this project. A focused dataset has been developed to streamline data collection and 
provide some standardization. Data collection is ongoing and members interested in 
contributing to the ITMIG effort are strongly encouraged to participate. Datasets can 
be easily uploaded through the Hubzero website, and data readily viewed through the 
online platform. Concurrently a Prospective database has been developed to collect data 
on new patients going forward on an ongoing basis, using standardized measures and 
definitions as previously described by ITMIG. The web-based interface for data entry 
provides ease of use and an intuitive data viewer which allows the user immediate access 
to their data. The Prospective database allows for a much greater level of detail in the 
data collection, which should prove extremely valuable. Collectively, the Retrospective 
and Prospective databases will provide an invaluable resource for research and will be 
made available to ITMIG members and investigators for approved research proposals. 
In addition to the clinical data, linkages to existing tissue samples are noted as well, 
opening up opportunities for collaborative translational research. Members interested in 
participating, or contributing to the Database projects are highly encouraged to contact 
James Huang (huangj@mskcc.org) for more details.
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